Supplements 1–5  •  Supplements 6–10  •  Supplements 11–15  •  Supplements 16–18

VOLUME 5, NUMBER 2, SUPPLEMENT 1 (February 2008)

Genetic testing and management of patients
with BRCA1/2-positive breast and ovarian
cancers

Linda D. Bosserman, MD, FACP, and Raquel Caldera, PA-C

Wilshire Oncology Medical Group, Inc., La Verne, CA

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 3, SUPPLEMENT 2 (March 2008)

Emerging therapies in advanced melanoma

Michael B. Atkins, MD, Michael K. K. Wong, MD, PhD, FRCPC,
Mario Sznol, MD, and Keith T. Flaherty, MD

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 4, SUPPLEMENT 3 (April 2008)

New taxane alternatives for the treatment of
advanced breast cancer

Edith A. Perez, MD

Mayo Clinic, Jacksonville, FL

Hope S. Rugo, MD

UCSF Helen Diller Family Comprehensive Cancer Center

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 5, SUPPLEMENT 4 (May 2008)

Improving the therapeutic index of taxane-based therapy

William J. Gradishar, MD, FACP

The Robert H. Lurie Comprehensive Cancer Center

Hope S. Rugo, MD

UCSF Helen Diller Family Comprehensive Cancer Center

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 7, SUPPLEMENT 5 (July 2008)

CURRENT CLINICAL TRIALS

The Patupilone in Ovarian Cancer Study

Peter E. Schwartz, MD

Yale School of Medicine and Yale Cancer Center, New Haven, CT

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 6, SUPPLEMENT 6 (June 2008)

Advancements in the treatment of mCRC:
improvements in the management of liver metastases

Axel Grothey, MD

Mayo Clinic, Rochester, MN

Michael A. Choti, MD, MBA, FACS

Department of Surgery, Johns Hopkins Hospital, Baltimore, MD

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 6, SUPPLEMENT 7 (June 2008)

Community translations: the expanding role of 
nab-paclitaxel

Jame Abraham, MD, guest editor

West Virginia University, Morgantown, WV

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 7, SUPPLEMENT 8 (July 2008)

Current strategies using novel taxane therapies for
advanced-stage breast cancer

Lee S. Schwartzberg, MD, FACP

The West Clinic, Memphis, TN

Ronald J. Scheff, MD

Weill Medical College of Cornell University, New York, NY

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 9, SUPPLEMENT 9 (September 2008)

A disease in transition: incorporating novel agents
into the treatment of multiple myeloma

Amitabha Mazumder, MD, Deborah S. Doss, RN, OCN,
Larry J. Rosenberg, PhD. and Ricky Newton, CPA

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 9, SUPPLEMENT 10 (September 2008)

CURRENT CLINICAL TRIALS

First-line treatment of locally advanced or metastatic
gastric or esophagogastric junction adenocarcinoma
with ECX and AMG 102

Ross C. Donehower, MD

Johns Hopkins University School of Medicine, Baltimore, MD

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 9, SUPPLEMENT 11 (September 2008)

CURRENT CLINICAL TRIALS

PRISM: a study of second-line panitumumab monotherapy
for treatment of advanced head and neck cancer

David R. Spigel, MD

Sarah Cannon Research Institute, Nashville, TN

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 10, SUPPLEMENT 12 (October 2008)

The role of pharmacogenetics in the management of
fluorouracil-based toxicity

L. Wayne Keiser, MD

Redwood Regional Medical Group, Santa Rosa, CA

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 10, SUPPLEMENT 13 (October 2008)

CURRENT CLINICAL TRIALS

Evaluating the addition of AMG 655 to mFOLFOX6/
bevacizumab in metastatic colorectal cancer

Charles S. Fuchs, MD, and Leonard B. Saltz, MD

Dana-Farber Cancer Institute, Boston, MA, and
Memorial Sloan-Kettering Cancer Center, New York, NY

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 10, SUPPLEMENT 14 (October 2008)

CURRENT CLINICAL TRIALS

PARTNER: a study of panitumumab plus chemotherapy for
first-line treatment of advanced head and neck cancer

Lori J. Wirth, MD

Dana-Farber Cancer Institute, Boston, MA

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 10, SUPPLEMENT 15 (October 2008)

CURRENT CLINICAL TRIALS

AMG 479 in combination with exemestane or fulvestrant
in postmenopausal women with locally advanced or
metastatic breast cancer

Peter A. Kaufman, MD

Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 11, SUPPLEMENT 16 (November 2008)

CURRENT CLINICAL TRIALS

SPIRITT: second-line treatment of metastatic colorectal
cancer with FOLFIRI plus panitumumab or bevacizumab

J. Randolph Hecht, MD, and Allen L. Cohn, MD

David Geffen School of Medicine at UCLA, Los Angeles, CA, and
Rocky Mountain Cancer Center, Denver, CO

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 11, SUPPLEMENT 17 (November 2008)

CURRENT CLINICAL TRIALS

A phase Ib/II study of AMG 655 or AMG 479 in combination
with gemcitabine for metastatic pancreatic cancer

Hedy Lee Kindler, MD

University of Chicago Medical Center, Chicago, IL

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT

VOLUME 5, NUMBER 11, SUPPLEMENT 18 (November 2008)

CURRENT CLINICAL TRIALS

AMG 386 plus sorafenib in metastatic renal cell carcinoma

Brian I. Rini, MD

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Complete Table of Contents  FREE FULL TEXT IN PDF FORMAT